Maziar Mike Doustdar, who was named as Novo Nordisk’s new CEO last week, spoke on a second quarter earnings call of ...

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

China has massive unmet medical needs, Mike Doustdar, who took over as CEO of Novo Nordisk today, after previously leading ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

Sales of Novo Nordisk's blockbuster Wegovy obesity drug rose 67% in the second quarter despite continued competition from ...

The outgoing chief executive of Novo Nordisk has revealed plans to ramp-up cost cutting 'efficiencies' across the business, ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Effective August 7, 2025, Maziar Mike Doustdar will succeed Lars Fruergaard Jørgensen as Novo Nordisk president and chief ...

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

Danish leader will face a challenging landscape among competitors ...

Novo Nordisk announced company veteran Maziar Mike Doustdar as its next CEO, as the firm struggles to regain its dominance in ...

Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective ...